High-grade progression confers poor survival in pancreatic neuroendocrine tumors
AffiliationDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
MetadataShow full item record
AbstractIntroduction: Little is known about how pancreatic neuroendocrine tumors (PanNETs) evolve over time and if changes toward a more aggressive biology correlate with prognosis. The purpose of this study was to characterize changes in PanNET differentiation and proliferation over time and to correlate findings to overall survival (OS). Patients and methods: In this retrospective cohort study, we screened 475 PanNET patients treated at Uppsala University Hospital, Sweden. Sporadic patients with baseline and follow-up tumor samples were included. Pathology reports and available tissue sections were reevaluated with regard to tumor histopathology and Ki-67 index. Results: Forty-six patients with 106 tumor samples (56 available for pathology reevaluation) were included. Median Ki-67 index at diagnosis was 7% (range 1-38%), grade 1 n = 8, grade 2 n = 36, and grade 3 n = 2. The median change in Ki-67 index (absolute value; follow-up - baseline) was +14% (range -11 to +80%). Increase in tumor grade occurred in 28 patients (63.6%), the majority from grade 1/2 to grade 3 (n = 24, 54.5%). The patients with a high-grade progression had a median OS of 50.2 months compared to 115.1 months in patients without such progression (hazard ratio 3.89, 95% CI 1.91-7.94, p < 0.001). Conclusions: A longitudinal increase in Ki-67 index and increase in tumor grade were observed in a majority of PanNETs included in this study. We propose that increase in Ki-67 index and high-grade progression should be investigated further as important biomarkers in PanNET.
CitationBotling J, Lamarca A, Bajic D, Norlen O, Lonngren V, Kjaer J, et al. High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2020;110(11-12):891-8.
- Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
- Authors: Farrell JM, Pang JC, Kim GE, Tabatabai ZL
- Issue date: 2014 Oct
- Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms.
- Authors: Sigel CS, Guo H, Sigel KM, Zhang M, Rekhtman N, Lin O, Klimstra DS, Jungbluth AA, Tang LK
- Issue date: 2017 Mar
- Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
- Authors: Mandair D, Khan MS, Lopes A, Furtado O'Mahony L, Ensell L, Lowe H, Hartley JA, Toumpanakis C, Caplin M, Meyer T
- Issue date: 2021 Mar 8
- Reconsideration of Clinicopathologic Prognostic Factors in Pancreatic Neuroendocrine Tumors for Better Determination of Adverse Prognosis.
- Authors: Aysal A, Agalar C, Egeli T, Unek T, Oztop I, Obuz F, Sagol O
- Issue date: 2021 Dec
- The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age.
- Authors: Partelli S, Muffatti F, Rancoita PMV, Andreasi V, Balzano G, Crippa S, Doglioni C, Rubini C, Zamboni G, Falconi M
- Issue date: 2019 May